In a report released today, Louise Chen from Cantor Fitzgerald assigned a Buy rating to Theravance Biopharma (NASDAQ: TBPH), with a price target of $55. The company’s shares opened today at $23.14, close to its 52-week low of $21.27.
Chen said:
“We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its four key programs (JAK Inhibitor, NEP Inhibitors, TD-9855, Revefenacin), all of which have data expected this year. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $55.”
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.0% and a 39.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Theravance Biopharma is Strong Buy and the average price target is $42.75, representing an 84.7% upside.
In a report issued on May 9, Needham also maintained a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.44 and a one-year low of $21.27. Currently, Theravance Biopharma has an average volume of 246.4K.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
